- Home
- EXEL vs ENTG Comparison
EXEL vs ENTG Comparison
Compare EXEL & ENTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- ENTG
- Stock Information
- Founded
- EXEL 1994
- ENTG 1966
- Country
- EXEL United States
- ENTG United States
- Employees
- EXEL N/A
- ENTG N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- ENTG Plastic Products
- Sector
- EXEL Health Care
- ENTG Industrials
- Exchange
- EXEL Nasdaq
- ENTG Nasdaq
- Market Cap
- EXEL 9.8B
- ENTG N/A
- IPO Year
- EXEL 2000
- ENTG 2000
- Fundamental
- Price
- EXEL $36.31
- ENTG $75.80
- Analyst Decision
- EXEL Buy
- ENTG Strong Buy
- Analyst Count
- EXEL 18
- ENTG 9
- Target Price
- EXEL $37.59
- ENTG $113.22
- AVG Volume (30 Days)
- EXEL 2.3M
- ENTG 3.4M
- Earning Date
- EXEL 05-13-2025
- ENTG 05-07-2025
- Dividend Yield
- EXEL N/A
- ENTG 0.52%
- EPS Growth
- EXEL 170.77
- ENTG N/A
- EPS
- EXEL 1.76
- ENTG 2.04
- Revenue
- EXEL $2,168,701,000.00
- ENTG $3,243,408,000.00
- Revenue This Year
- EXEL $5.78
- ENTG $7.40
- Revenue Next Year
- EXEL $10.94
- ENTG $10.20
- P/E Ratio
- EXEL $20.74
- ENTG $37.79
- Revenue Growth
- EXEL 18.50
- ENTG N/A
- 52 Week Low
- EXEL $20.14
- ENTG $60.75
- 52 Week High
- EXEL $40.26
- ENTG $147.57
- Technical
- Relative Strength Index (RSI)
- EXEL 49.28
- ENTG 47.19
- Support Level
- EXEL $34.90
- ENTG $70.92
- Resistance Level
- EXEL $40.26
- ENTG $81.95
- Average True Range (ATR)
- EXEL 1.18
- ENTG 3.65
- MACD
- EXEL -0.13
- ENTG 0.93
- Stochastic Oscillator
- EXEL 40.67
- ENTG 57.78
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.